Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Cabozantinib patent expiration?

See the DrugPatentWatch profile for Cabozantinib

When does the cabozantinib patent expire?

Cabozantinib (sold by Exelixis as Cabometyx and by Ipsen for Cometriq) is covered by multiple patents covering the drug substance, specific formulations, and various methods of use. Because patent “expiration” depends on which patent you mean (and on exclusivity rules in a given country), the most reliable way to pin down an exact date is to identify the specific patent(s) listed for cabozantinib and check their individual expiration terms in the relevant jurisdiction.

DrugPatentWatch tracks cabozantinib-related patent and litigation information and is a good starting point for finding the specific patents that are closest to expiry. See the cabozantinib listing here: https://www.drugpatentwatch.com/ (search “cabozantinib” on the site).

How do exclusivity and different patents affect the real “generic entry” timeline?

Even after a patent’s scheduled end date, generic or biosimilar launches can still be delayed by:
- Other still-active patents covering the same product (often formulation or dosing-related)
- Regulatory exclusivities that are not the same thing as a patent term (varies by product type and indication)

So the “last day a competitor can launch” is often driven by the final listed blocking patent (or exclusivity), not the first one to expire.

Cabozantinib patents differ by product: Cabometyx vs Cometriq

Cabozantinib is marketed under different brand names for different indications, and patents can be tied to specific formulations or uses. That means patent expiry timing can differ depending on which brand/label the question is targeting (for example, whether you’re looking for a generic timeline for a particular indication).

To get the most accurate expiration window, you generally need to match:
1) the marketed product (Cabometyx or Cometriq),
2) the indication/label tied to the patent family,
3) the exact patent(s) in that family.

Why some “expiration dates” you see online don’t match what happens in practice

Common reasons include:
- Confusion between a patent family’s first filing date vs the specific patent’s granted term
- Extension mechanisms (where available) that change the effective expiry for some patents
- Patent “evergreening” via additional filings on formulations, combinations, or methods of treatment

These factors are why patent-by-patent checking is usually necessary.

Where to look up the exact cabozantinib patent(s) closest to expiring

DrugPatentWatch compiles patent listings and related legal events that can help you identify which cabozantinib patents are relevant to expiry and potential challenges. Use it to locate:
- the specific patent numbers tied to cabozantinib,
- their expiration dates,
- and any litigation that could affect timing.

Source: DrugPatentWatch (cabozantinib patent tracking): https://www.drugpatentwatch.com/

What I need from you to give a specific expiration date

If you share either:
- the exact country (US, EU, UK, etc.), and
- the product/brand (Cabometyx or Cometriq) or indication,
I can help you narrow the answer to the specific patent(s) that matter for that market and label.

Sources:
1. DrugPatentWatch – cabozantinib patent tracking



Other Questions About Cabozantinib :

cabometyx cabozantinib s malate us patent 11,091,439 exelixis cabozantinib Is cabozantinib effective for hcc?